Esperion Therapeutics ESPR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $167.85M+16.0% | $144.76M+76.0% | $82.25M-34.1% | $124.78M-51.8% | ||
| $448.21M+70.5% | $262.94M+56.2% | $168.33M+42.4% | $118.18M+41.1% | ||
| $105.12M+11.3% | $94.49M+44.0% | $65.62M+86.4% | $35.2M+2.3% | ||
| $462.57M+36.9% | $338M+68.1% | $201.07M-18.5% | $246.68M-25.0% | ||
| $338K+33.1% | $254K— | $0-100% | $164K-75.3% | ||
| $56K0.0% | $56K0.0% | $56K0.0% | $56K0.0% | ||
| $465.89M+35.5% | $343.82M+67.1% | $205.8M-17.0% | $247.94M-35.0% | ||
| $65.07M+26.0% | $51.65M+62.8% | $31.72M+37.7% | $23.04M+31.2% | ||
| $34.48M+305% | $8.52M-66.5% | $25.4M+624% | $3.51M-38.3% | ||
| $300.81M+22.2% | $246.23M+57.6% | $156.22M+69.2% | $92.31M+25.8% | ||
| $152.22M+8.0% | $140.97M— | $0— | —— | ||
| $767.85M+4.8% | $732.54M+10.9% | $660.79M+15.6% | $571.72M-1.2% | ||
| 480M0.0% | 480M0.0% | 480M+100% | 240M+100% | ||
| -$1.62B-1.4% | -$1.6B-3.3% | -$1.55B-15.6% | -$1.34B-21.1% | ||
| -$301.97M+22.3% | -$388.72M+14.6% | -$454.99M-40.5% | -$323.78M-64.4% | ||
| $465.89M+35.5% | $343.82M+67.1% | $205.8M-17.0% | $247.94M-35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Esperion Therapeutics's total assets?
- Esperion Therapeutics (ESPR) holds $462.5M in total assets, up 42.7% year over year.
- How much debt does Esperion Therapeutics have?
- Esperion Therapeutics carries $155.2M in total debt against -$307.9M of shareholders' equity, a debt-to-equity ratio of 0.75.
- How much cash does Esperion Therapeutics have?
- Esperion Therapeutics holds $156.2M in cash and equivalents.
- Can Esperion Therapeutics cover its short-term obligations?
- Its current ratio is 1.53 — current assets exceed current liabilities.
- Where does Esperion Therapeutics's balance sheet data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
